Totaligent (OTC:TGNT) announced that President and board member Ivan Klarich delivered a featured presentation at the Uncharted Impact x A-Team Hub Accelerator, a U.S.–Taiwan innovation forum at Warner Brothers Studios.
He highlighted the Aetherium Medical platform’s role in connecting AI-enabled biologics and regenerative therapies with patients via ethical, compliant medical tourism channels in the Asia-Pacific region and noted a follow-up speaking invitation in Taipei in August 2026.
Loading…
Loading translation…
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
BOCA RATON, Fla., June 08, 2026 (GLOBE NEWSWIRE) — Totaligent, Inc. (OTCID: TGNT) (“Totaligent” or “the Company”), an emerging leader in specialized infrastructure for the biologics space and intelligent business marketing data, today highlighted the participation of Ivan Klarich, President and Board Member of Totaligent and founder of the Aetherium Medical platform, at the Uncharted Impact x A-Team Hub Accelerator. This prestigious U.S.–Taiwan innovation forum was hosted at Warner Brothers Studios in Burbank, California.
The event convened global investors, government representatives, startup leaders, and innovation ecosystem participants to drive cross-border collaboration and accelerate high-impact technologies. Klarich delivered a featured presentation titled “Tomorrow’s Medicine Today: Access and Global Deployment – Bringing Innovation to the Real World.” His remarks emphasized strategies to overcome infrastructure, accessibility, and regulatory barriers to deliver advanced therapies to patients worldwide.
“Aetherium Medical, now fully integrated within Totaligent, exemplifies a transformative model for bridging clinical innovation with scalable global access,” said Klarich. “This is groundbreaking science that ensures patients can truly benefit from these advanced therapies.”
The Aetherium Medical platform, acquired by Totaligent through a strategic acqui-hire, serves as critical infrastructure connecting innovative biotechnology companies, particularly those developing AI-enabled biologics and regenerative therapies, with patients via ethical, efficient, and compliant medical-tourism channels in the Asia-Pacific region. By leveraging specialized cold-chain logistics, turnkey commercialization services, and robust governance, Aetherium provides the foundational “picks-and-shovels” infrastructure for the rapidly expanding biologics sector, anchored by Japan’s progressive regulatory environment.
The forum featured a high-level Taiwanese delegation, including representatives from a leading accelerator and venture capital firm that works closely with the Taiwan National Development Council. Additional attendees included officials from Taiwan’s National Development Council, which co-invests with private capital in promising ventures, along with a select cohort of young, government-supported entrepreneurs participating in a month-long U.S. immersion program.
Building on this momentum, Klarich has been invited to speak in Taipei, Taiwan, in August 2026 as part of a week-long international entrepreneur delegation program. This engagement will further strengthen U.S.-Taiwan ties and advance shared goals in healthcare innovation and global patient access.
About Aetherium Medical
Aetherium Medical is a specialized infrastructure platform that bridges innovative biotechnology companies—particularly those advancing AI-enabled biologic therapies—with global patients through ethical, efficient, and compliant medical-tourism channels in the Asia-Pacific region. The platform leverages partnerships such as GloMed Solutions for cold-chain logistics, commercialization services, and ethical governance. For more information, visit https://www.aetheriummedical.com/.
About Totaligent, Inc.
Totaligent, Inc. (OTCID: TGNT) is an innovative provider of omni-channel digital marketing solutions, specializing in targeted outreach to medical, pharmaceutical, and biotechnology professionals through its proprietary database of over one billion records. The Company is focused on strategic growth in high-potential sectors, including advanced biologics commercialization. For more information, visit www.totaligent.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Such risks include, but are not limited to, the ability to achieve performance milestones, successfully integrate the Aetherium Assets, execute international collaboration initiatives, secure necessary approvals, and advance the Company’s growth strategy. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update any forward-looking statements.
Investor Relations
ir@totaligent.com
Ben Hansel
(720) 288-8495
FAQ
What did Totaligent (OTC:TGNT) announce about Ivan Klarich’s role at the U.S.–Taiwan innovation forum?
Ivan Klarich delivered a featured presentation at the Uncharted Impact x A-Team Hub Accelerator. According to Totaligent, his talk focused on overcoming infrastructure, accessibility, and regulatory barriers to bring advanced biologic therapies to patients worldwide through scalable global deployment strategies.
What is the Aetherium Medical platform within Totaligent (OTC:TGNT)?
Aetherium Medical is a platform now fully integrated within Totaligent after a strategic acqui-hire. According to Totaligent, it connects innovative biotechnology companies, especially AI-enabled biologics and regenerative therapies developers, with patients via ethical, efficient, compliant medical tourism channels in the Asia-Pacific region.
How does Aetherium Medical support biologics and medical tourism for Totaligent (OTC:TGNT)?
Aetherium Medical provides specialized infrastructure for biologics and medical tourism. According to Totaligent, it leverages cold-chain logistics, turnkey commercialization services, and governance to link biotech innovators with patients, particularly in the Asia-Pacific region anchored by Japan’s progressive regulatory environment.
What future engagement in Taiwan was announced by Totaligent (OTC:TGNT)?
Totaligent announced Ivan Klarich was invited to speak in Taipei in August 2026. According to Totaligent, this week-long international entrepreneur delegation program aims to deepen U.S.–Taiwan ties and support shared goals in healthcare innovation and global patient access.
Who attended the Uncharted Impact x A-Team Hub Accelerator with Totaligent (OTC:TGNT)?
The forum gathered global investors, government representatives, startup leaders, and innovation ecosystem participants. According to Totaligent, a high-level Taiwanese delegation attended, including representatives linked to Taiwan’s National Development Council and young entrepreneurs in a month-long U.S. immersion program.
